DVAX vs. IONS, ALKS, FOLD, LGND, GERN, MNKD, BCRX, CLDX, NVAX, and MYGN
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry.
Dynavax Technologies vs.
Dynavax Technologies (NASDAQ:DVAX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, community ranking, analyst recommendations, valuation, media sentiment and institutional ownership.
97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Ionis Pharmaceuticals received 223 more outperform votes than Dynavax Technologies when rated by MarketBeat users. However, 65.97% of users gave Dynavax Technologies an outperform vote while only 60.31% of users gave Ionis Pharmaceuticals an outperform vote.
In the previous week, Dynavax Technologies had 8 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 22 mentions for Dynavax Technologies and 14 mentions for Ionis Pharmaceuticals. Dynavax Technologies' average media sentiment score of 0.93 beat Ionis Pharmaceuticals' score of 0.38 indicating that Dynavax Technologies is being referred to more favorably in the media.
Dynavax Technologies has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
Dynavax Technologies currently has a consensus price target of $23.00, indicating a potential upside of 85.63%. Ionis Pharmaceuticals has a consensus price target of $60.65, indicating a potential upside of 87.88%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Dynavax Technologies.
Dynavax Technologies has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.
Dynavax Technologies has a net margin of 7.85% compared to Ionis Pharmaceuticals' net margin of -44.58%. Dynavax Technologies' return on equity of 3.19% beat Ionis Pharmaceuticals' return on equity.
Summary
Dynavax Technologies beats Ionis Pharmaceuticals on 13 of the 19 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:DVAX) was last updated on 1/16/2025 by MarketBeat.com Staff
